



**IT Services** 

11 January 2020

# Commentary lack new growth impetus

Infosys (INFO)'s Q3FY20 operating performance fell tad short on expectations led by operating margin miss (EBIT margins at 21.9% V/s our est. of 22.4%). Revised guidance was no surprise and imply soft starting grounds for FY21. Management commentary provided no increamental impetus to suggest improvement in growth outlook. We keep FY21/FY22 EPS estimates broadly unchanged and roll forward to a Dec'20 TP of Rs 840 (Rs 860 earlier, reset target P/E to 18x V/s 19x). Retain ADD.

Ruchi Burde research@bobcaps.in

Clean chit on whistleblower allegations: Audit committee investigation report dismissed whistblower allegations and concluded no financial impropriety or executive misconduct. This will ease overhang on the stock and render relief to multiple stakeholders.

Tad operating margin miss: While INFO's 1% QoQ cc revenue growth was inline, EBIT margins at 21.9% (up 20bps) missed street and our estimates of an QoQ improvement of 40-50bps and 70bps respectively. Operating metrics were a mixed bag, with positives from 1) onsite/offshore mix, 2) attrition, and a weak show from 1) BFSI vertical, 2) performance of top clients.

Revised guidance was no surprise: INFO now expects FY20 revenue growth of 10-10.5% YoY CC (from 9-10% guided earlier). This imply 0%-1.5% QoQ cc growth in Q4FY20 at lower and top end respectively (which is inline). Operating margin guidance unchanged at 21% to 23%.

Renewal still dominate deal wins: Deal win TCV at US\$1.8bn marked seasonal moderation (down 36% QoQ) albeit up 15% YoY. Higher share of renewals continued for 3<sup>rd</sup> consecutive quarter leading to 9mFY19 renewal deal proportion to 75% V/s 53% in 9mFY19.

Ticker/Price	INFO IN/Rs 738
Market cap	US\$ 45.3bn
Shares o/s	4,349mn
3M ADV	US\$ 121.1mn
52wk high/low	Rs 847/Rs 615
Promoter/FPI/DII	13%/35%/52%
Cauragi NICE	

Source: NSE

### STOCK PERFORMANCE




Source: NSE

### **KEY FINANCIALS**

Y/E 31 Mar	FY18A	FY19A	FY20E	FY21E	FY22E
Total revenue (Rs mn)	7,05,220	8,26,760	9,04,520	9,83,395	10,88,229
EBITDA (Rs mn)	1,90,100	2,08,890	2,24,386	2,53,371	2,80,381
Adj. net profit (Rs mn)	1,60,280	1,54,100	1,65,074	1,81,291	2,04,353
Adj. EPS (Rs)	36.9	35.4	38.9	42.7	48.1
Adj. EPS growth (%)	17.3	(4.0)	9.9	9.8	12.7
Adj. ROAE (%)	23.9	24.5	25.8	25.6	26.0
Adj. P/E (x)	20.0	20.9	19.0	17.3	15.3
EV/EBITDA (x)	15.4	14.4	13.5	11.9	10.5




FIG 1 - 9MFY20 NEW DEAL TCV DOWN 18% YOY



Source: Company, BOBCAPS Research

FIG 2 – 20BPS QOQ EBIT MARGIN IMPROVEMENT WAS SHORT ON EXPECTATIONS



Source: Company, BOBCAPS Research

FIG 3 – ATTRITION EASED FOR 2<sup>ND</sup> QUARTER IN ROW






FIG 4 – DEC'19 QUARTER RESULT SUMMARY

(Rs mn)	Q1FY19	Q2FY19	Q3FY19	Q4FY19	Q1FY20	Q2FY20	Q3FY20	Y <sub>0</sub> Y (%)	Q <sub>0</sub> Q (%)	9mFY19	9mFY20	Y <sub>0</sub> Y (%)
Revenues (US\$ mn)	2,831	2,921	2,987	3,060	3,131	3,210	3,243	8.6	1.0	8,739	9,584	9.7
Revenue	1,91,280	2,06,090	2,14,000	2,15,390	2,18,030	2,26,290	2,30,920	7.9	2.0	6,11,370	6,75,240	10.4
Operating Expenditure	1,41,550	1,52,520	1,59,900	1,63,900	1,66,510	1,69,900	1,72,910	8.1	1.8	4,53,970	5,09,320	12.2
Cost of revenues	1,18,520	1,28,180	1,34,360	1,37,520	1,40,980	1,43,520	1,46,360	8.9	2.0	3,81,060	4,30,860	13.1
as % of sales	62.0	62.2	62.8	63.8	64.7	63.4	63.4	-	-	62.3	63.8	-
SG&A expenses	23,030	24,340	25,540	26,380	25,530	26,380	26,550	4.0	0.6	72,910	78,460	7.6
as % of sales	12.0	11.8	11.9	12.2	11.7	11.7	11.5	-	-	11.9	11.6	-
EBITDA	49,730	53,570	54,100	51,490	51,520	56,390	58,010	7.2	2.9	1,57,400	1,65,920	5.4
Depreciation	4,360	4,630	5,800	5,310	6,810	7,270	7,360	26.9	1.2	14,790	21,440	45.0
EBIT	45,370	48,940	48,300	46,180	44,710	49,120	50,650	4.9	3.1	1,42,610	1,44,480	1.3
Other Income	7,260	7,390	7,530	6,650	7,360	6,260	8,270	-	-	22,180	21,890	(1.3)
PBT	52,630	56,330	55,830	52,830	52,070	55,380	58,920	5.5	6.4	1,64,790	1,66,370	1.0
Total Tax	13,810	15,230	15,220	12,050	13,650	14,590	13,830	(9.1)	(5.2)	44,260	42,070	(4.9)
Adjusted PAT	38,820	41,100	40,610	40,780	38,420	40,790	45,090	11.0	10.5	1,20,530	1,24,300	3.1
(Profit)/loss from JV's/Ass/MI	0	0	0	0	0	0	0	-	-	0	0	-
APAT after MI	38,820	41,100	40,610	40,780	38,420	40,790	45,090	11.0	10.5	1,20,530	1,24,300	3.1
Extra ordinary items	(2,700)	0	(4,510)	0	0	0	0	-	-	(7,210)	0	-
Reported PAT	36,120	41,100	36,100	40,780	38,420	40,790	45,090	24.9	10.5	1,13,320	1,24,300	9.7
Reported EPS	8.3	9.4	8.3	9.4	8.8	9.4	10.5	26.7	11.2	26	29	10.4
Margins (%)								(bps)	(bps)			(bps)
EBIDTA	26.0	26.0	25.3	23.9	23.6	24.9	25.1	(16)	20	25.7	24.6	(117)
EBIT	23.7	23.7	22.6	21.4	20.5	21.7	21.9	(64)	23	23.3	21.4	(193)
EBT	27.5	27.3	26.1	24.5	23.9	24.5	25.5	(57)	104	27.0	24.6	(232)
PAT	18.9	19.9	16.9	18.9	17.6	18.0	19.5	266	150	19.7	18.4	(131)
Effective Tax rate	26.2	27.0	27.3	22.8	26.2	26.3	23.5	(378.9)	(287)	26.9	25.3	(157)

FIG 5 – DEC'19 QUARTER OPERATING METRICS

	Q3FY20 (% Contr. to Revenue)	Q <sub>0</sub> Q (%)	Y <sub>0</sub> Y (%)
TCV of deal wins (in US\$ mn)	1,813	(36.3)	15.5
Digital Revenues	40.6	7.1	39.9
Revenue breakup-Geography			
North America	61.3	0.9	10.2
Europe	24.4	2.3	9.5
India	2.8	4.8	16.9
ROW	11.5	(1.5)	(2.5)
Revenue by industry groups			
BFSI	31.5	(0.2)	5.2
Retail	15.3	1.7	1.3
Communications	13.0	0.3	18.6
Energy, Utilities, Resources and Services	12.8	(1.3)	8.6
Manufacturing	10.3	3.0	10.7
Hi Tech	7.6	1.0	13.0



	Q3FY20 (% Contr. to Revenue)	Q <sub>0</sub> Q (%)	Y <sub>0</sub> Y (%)
Life Sciences	6.7	5.8	17.3
Others	2.8	8.8	8.6
Client concentration			
Top Client	3.0	(5.3)	(4.2)
Top 10 Clients	18.9	(0.6)	6.9
Non Top 10 Clients	81.1	1.4	9.0
	0.057/0.0		
	Q3FY20	Q2FY20	Q3FY19
Onsite-Offshore Effort Split	Q3FY20	Q2FY20	Q3FY19
Onsite-Offshore Effort Split Onsite	<b>Q3FY20</b> 27.7	<b>Q2FY20</b> 28.2	<b>Q3FY19</b> 28.7
<u>'</u>	,	`	•
Onsite	27.7	28.2	28.7
Onsite Offshore	27.7	28.2	28.7



# Valuation methodology

In our view Infosys management commentary provided no increamental impetus to suggest improvement in growth outlook. Management reiterated challenging outlook for BFSI and retail vertical (accounting for ~47% of revenues). Manufacturing, Communication and Hi Tech are likely to be growth supportive. Auto vertical is soft patch in manufacturing while couple of client specific issue linger in Energy vertical.

Moreover 18% YoY decline in new deal wins in 9mFY20 further undermine growth visibility. Q4FY20 implied guidance hint at softer start to FY21E (compared to FY20). We build 10%/11.1% dollar revenue and EPS CAGR over FY20-22. We keep FY21/22E EPS largely unchanged (4.6% FY20 EPS increase bakes in higher other income and lower taxes beside margins operational tweak). Retain ADD with revised TP of Rs840 (set at target 18x P/E V/s 19x earlier factoring in moderation in growth traction). Beyond reset of valuations for clear title on whistblower allegations, stock performance hinges on operating margin improvement clarity (over FY18 to FY20 - EBIT margin difference between Infosys and TCS has increased from 50bps to ~280bps). Prefer TCS and HCL Tech over Infosys.

FIG 6 - REVISED EARNINGS

(D. )		FY20E			FY21E			FY22E	
(Rs mn)	Old	New	Change (%)	Old	New	Change (%)	Old	New	Change (%)
Revenues (US\$ mn)	12,825	12,859	0.3	13,975	14,048	0.5	15,465	15,546	0.5
YoY revenue growth (%)	8.7	9.0	-	9.0	9.2	-	10.7	10.7	-
Revenues	8,91,741	9,04,520	1.4	9,78,255	9,83,395	0.5	10,82,541	10,88,229	0.5
EBITDA	2,18,425	2,24,386	2.7	2,52,046	2,53,371	0.5	2,78,916	2,80,381	0.5
EBITDA margins (%)	24.5	24.8	-	25.8	25.8	-	25.8	25.8	-
EBIT margins (%)	21.4	21.6	-	22.7	22.6	-	23.0	22.9	-
Net profits	1,57,751	1,65,074	4.6	1,81,264	1,81,291	0.0	2,04,072	2,04,353	0.1
EPS (Rs)	37.2	38.9	4.6	42.7	42.7	0.0	48.1	48.1	0.1

Source: BOBCAPS Research

FIG 7 - RELATIVE STOCK PERFORMANCE





# Key risks

Downside risks to our estimates are:

- a more pronounced adverse impact of global trade tensions, Brexit and other negative external events, leading to weaker-than-expected demand;
- more stringent visa regulations;
- below-expected operating margins for new engagements/renewals; and
- leadership changes.



### **FINANCIALS**

# Income Statement

Y/E 31 Mar (Rs mn)	FY18A	FY19A	FY20E	FY21E	FY22E
Total revenue	7,05,220	8,26,760	9,04,520	9,83,395	10,88,229
EBITDA	1,90,100	2,08,890	2,24,386	2,53,371	2,80,381
Depreciation	18,620	20,100	28,655	31,156	31,156
EBIT	1,71,480	1,88,790	1,95,732	2,22,215	2,49,226
Net interest income/(expenses)	26,130	21,550	17,638	26,129	30,711
Other income/(expenses)	32,400	28,830	27,328	26,129	30,711
Exceptional items	(1,180)	(7,210)	0	0	0
EBT	2,02,700	2,10,410	2,23,060	2,48,344	2,79,936
Income taxes	42,420	56,310	57,376	67,053	75,583
Extraordinary items	0	0	0	0	0
Min. int./Inc. from associates	0	0	610	0	0
Reported net profit	1,60,280	1,54,100	1,65,074	1,81,291	2,04,353
Adjustments	0	0	0	0	0
Adjusted net profit	1,60,280	1,54,100	1,65,074	1,81,291	2,04,353

# **Balance Sheet**

Y/E 31 Mar (Rs mn)	FY18A	FY19A	FY20E	FY21E	FY22E
Accounts payables	0	0	0	0	0
Other current liabilities	1,44,740	1,68,940	1,90,817	2,07,456	2,29,572
Provisions	4,920	5,230	7,434	8,083	8,944
Debt funds	0	0	0	0	0
Other liabilities	0	0	0	0	0
Equity capital	10,880	21,700	21,700	21,700	21,700
Reserves & surplus	6,38,360	5,85,160	6,50,873	7,23,072	8,04,455
Shareholders' fund	6,49,240	6,06,860	6,72,573	7,44,772	8,26,155
Total liabilities and equities	7,98,900	7,81,030	8,70,824	9,60,310	10,64,671
Cash and cash eq.	1,98,180	1,65,060	2,23,391	2,84,484	3,46,567
Accounts receivables	1,31,420	1,36,990	1,63,557	1,77,819	1,96,776
Inventories	0	0	0	0	0
Other current assets	42,610	46,550	47,085	51,190	56,648
Investments	1,21,630	1,24,990	1,24,990	1,24,990	1,24,990
Net fixed assets	1,46,010	1,49,560	1,47,634	1,44,478	1,44,822
CWIP	0	0	0	0	0
Intangible assets	0	0	0	0	0
Deferred tax assets, net	12,820	13,000	13,000	13,000	13,000
Other assets	1,46,230	1,44,880	1,51,166	1,64,348	1,81,868
Total assets	7,98,900	7,81,030	8,70,824	9,60,310	10,64,671



### Cash Flows

Y/E 31 Mar (Rs mn)	FY18A	FY19A	FY20E	FY21E	FY22E
Net income + Depreciation	1,10,630	1,74,200	1,93,729	2,12,447	2,35,509
Interest expenses	(23,600)	(28,830)	(27,328)	(26,129)	(30,711)
Non-cash adjustments	0	0	0	0	0
Changes in working capital	840	16,350	(9,307)	(14,262)	(18,956)
Other operating cash flows	43,780	(98,005)	73,287	0	0
Cash flow from operations	1,31,650	63,715	2,30,380	1,72,056	1,85,842
Capital expenditures	(19,980)	(23,650)	(26,729)	(28,000)	(31,500)
Change in investments	21,810	0	0	0	0
Other investing cash flows	43,500	28,830	27,328	26,129	30,711
Cash flow from investing	45,330	5,180	600	(1,871)	(789)
Equities issued/Others	50	(9,313)	(73,287)	0	0
Debt raised/repaid	0	0	0	0	0
Interest expenses	0	0	0	0	0
Dividends paid	(2,05,100)	(92,730)	(99,333)	(1,09,092)	(1,22,970)
Other financing cash flows	0	0	0	0	0
Cash flow from financing	(2,05,050)	(1,02,043)	(1,72,620)	(1,09,092)	(1,22,970)
Changes in cash and cash eq.	(28,070)	(33,148)	58,359	61,093	62,083
Closing cash and cash eq.	1,98,180	1,65,032	2,23,391	2,84,484	3,46,567

# Per Share

Y/E 31 Mar (Rs)	FY18A	FY19A	FY20E	FY21E	FY22E
Reported EPS	36.9	35.4	38.9	42.7	48.1
Adjusted EPS	36.9	35.4	38.9	42.7	48.1
Dividend per share	43.5	21.5	19.5	21.4	24.1
Book value per share	149.3	139.3	158.4	175.4	194.6

# Valuations Ratios

Y/E 31 Mar (x)	FY18A	FY19A	FY20E	FY21E	FY22E
EV/Sales	4.2	3.6	3.3	3.1	2.7
EV/EBITDA	15.4	14.4	13.5	11.9	10.5
Adjusted P/E	20.0	20.9	19.0	17.3	15.3
P/BV	4.9	5.3	4.7	4.2	3.8

# **DuPont Analysis**

Y/E 31 Mar (%)	FY18A	FY19A	FY20E	FY21E	FY22E
Tax burden (Net profit/PBT)	79.1	73.2	74.0	73.0	73.0
Interest burden (PBT/EBIT)	118.2	111.5	114.0	111.8	112.3
EBIT margin (EBIT/Revenue)	24.3	22.8	21.6	22.6	22.9
Asset turnover (Revenue/Avg TA)	86.4	104.7	109.5	107.4	107.5
Leverage (Avg TA/Avg Equity)	1.2	1.3	1.3	1.3	1.3
Adjusted ROAE	23.9	24.5	25.8	25.6	26.0

Source: Company, BOBCAPS Research | Note: TA = Total Assets



# Ratio Analysis

Y/E 31 Mar	FY18A	FY19A	FY20E	FY21E	FY22E
YoY growth (%)					
Revenue	3.0	17.2	9.4	8.7	10.7
EBITDA	2.2	9.9	7.4	12.9	10.7
Adjusted EPS	17.3	(4.0)	9.9	9.8	12.7
Profitability & Return ratios (%)					
EBITDA margin	27.0	25.3	24.8	25.8	25.8
EBIT margin	24.3	22.8	21.6	22.6	22.9
Adjusted profit margin	22.7	18.6	18.2	18.4	18.8
Adjusted ROAE	23.9	24.5	25.8	25.6	26.0
ROCE	29.6	31.0	32.6	35.7	38.7
Working capital days (days)					
Receivables	66	59	61	63	63
Inventory	0	0	0	0	0
Payables	101	93	97	100	99
Ratios (x)					
Gross asset turnover	4.6	5.6	6.1	6.7	7.5
Current ratio	3.5	2.8	3.0	3.1	3.3
Net interest coverage ratio	6.6	8.8	11.1	8.5	8.1
Adjusted debt/equity	(0.3)	(0.3)	(0.3)	(0.4)	(0.4)



### Disclaimer

#### Recommendations and Absolute returns (%) over 12 months

BUY - Expected return >+15%


ADD - Expected return from >+5% to +15%

REDUCE - Expected return from -5% to +5%

SELL - Expected return <-5%

Note: Recommendation structure changed with effect from 1 January 2018 (Hold rating discontinued and replaced by Add / Reduce)

#### HISTORICAL RATINGS AND TARGET PRICE: INFOSYS (INFO IN)



B - Buy, A - Add, R - Reduce, S - Sell

### Rating distribution

As of 31 December 2019, out of 83 rated stocks in the BOB Capital Markets Limited (BOBCAPS) coverage universe, 50 have BUY ratings, 18 are rated ADD, 9 are rated REDUCE and 6 are rated SELL. None of these companies have been investment banking clients in the last 12 months.

#### **Analyst certification**

The research analyst(s) authoring this report hereby certifies that (1) all of the views expressed in this research report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOBCAPS.

### General disclaimers

BOBCAPS is engaged in the business of Institutional Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS has obtained registration as a Research Entity under SEBI (Research Analysts) Regulations, 2014, having registration No.: INH000000040 valid till 03 February 2020. BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations

#### **INFOSYS**



expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities —that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may act as market makers or assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

In the US, this material is only for Qualified Institutional Buyers as defined under rule 144(a) of the Securities Act, 1933. No part of this document may be distributed in Canada or used by private customers in the United Kingdom.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

### Company-specific disclosures under SEBI (Research Analysts) Regulations, 2014

The research analyst(s) or his/her relatives do not have any material conflict of interest at the time of publication of this research report.

BOBCAPS or its research analyst(s) or his/her relatives do not have any financial interest in the subject company. BOBCAPS or its research analyst(s) or his/her relatives do not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

The research analyst(s) has not received any compensation from the subject company in the past 12 months. Compensation of the research analyst(s) is not based on any specific merchant banking, investment banking or brokerage service transactions.

BOBCAPS or its research analyst(s) is not engaged in any market making activities for the subject company.

The research analyst(s) has not served as an officer, director or employee of the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.